Echo Therapeutics to price public units sale with five-year warrants

Roth Capital will help raise proceeds for general corporate purposes

By Devika Patel

Knoxville, Tenn., Dec. 2 - Echo Therapeutics, Inc. plans to conduct a public offering of units, according to an S-1 filed Monday with the Securities and Exchange Commission.

The units each consist of one common share and one five-year warrant.

Roth Capital Partners, LLC is the bookrunner.

Proceeds will be used for general corporate purposes.

Franklin, Mass.-based Echo Therapeutics is a dual platform-enabled specialty therapeutics and diagnostics company.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.